All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Measurable residual disease (MRD) negativity is increasingly being investigated and used as a biomarker for treatment cessation in patients with multiple myeloma (MM) who are eligible for transplant.
However, MRD resurgence and progressive disease (PD) are observed in some patients posttreatment cessation guided by MRD-negativity; highlighting the importance of identifying risk factors and predictors of resurgence in this population to prevent disease progression.
Here, we summarize a report published by Guerrero et al.1 in Blood on the predictors of unsustained MRD-negativity in patients with MM who are eligible for transplant.
Figure 1. Hazard ratio for predictors of MRD-resurgence and PD*
CTC, circulating tumor cells; ISS, International Staging System.
*Adapted from Guerrero, et al.1
Key learnings |
---|
|
Subscribe to get the best content related to multiple myeloma delivered to your inbox